228.74 (0.32%)
As of Jan 09, 2024
Source:
Seagen is a biotechnology company that develops and commercializes targeted therapies to treat cancer. We are commercializing ADCETRIS , or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas, PADCEV , or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers, TUKYSA , or tucatinib, for the treatment of certain metastatic HER2-positive breast and colorectal cancers, and TIVDAK , or tisotumab vedotin-tftv, for the treatment of certain metastatic cervical cancers.
Country | United States |
Headquarters | bothell, washington |
Phone Number | 4255274000 |
Industry | manufacturing |
CEO | David R. Epstein |
Website | www.seagen.com |